We are live on ! Find out more
LPCN icon

Lipocine
LPCN

38 hedge funds and large institutions have $72.4M invested in Lipocine in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

950% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 2

267% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 3

144% more capital invested

Capital invested by funds: $29.7M → $72.4M (+$42.7M)

100% more funds holding

Funds holding: 19 → 38 (+19)

Holders
38
Holders Change
+19
Holders Change %
+100%
% of All Funds
1.02%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
21
Increased
11
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$7.85M
2
AC
Armistice Capital
New York
+$6.21M
3
SM
Sabby Management
Florida
+$5.29M
4
VM
VHCP Management
New York
+$4.38M
5
KCM
Kingdon Capital Management
New York
+$2.19M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$3.38M
2
VAM
Visium Asset Management
New York
-$511K
3
JGC
J. Goldman & Co
New York
-$109K
4
VKH
Virtu KCG Holdings
New York
-$97K
5
Goldman Sachs
Goldman Sachs
New York
-$5.34K

LPCN Hedge Fund Activity: Q2 2015 in Review

38 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2015, worth a combined $72.4M — up 144% from $29.7M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new LPCN positions and 2 closed out — a net gain of 19 holders — while 11 added to existing stakes and 3 trimmed.

The largest buyer was Invesco, opening a new position worth an estimated $7.85M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $3.38M sold.

  • 38 institutional investors held Lipocine (LPCN) as of Q2 2015, up from 19 in Q1 2015.
  • Funds reported $72.4M of Lipocine stock for Q2 2015, up 144% quarter-over-quarter.
  • 21 funds opened new Lipocine positions in Q2 2015 and 2 closed out, a net change of +19 holders.
  • The largest Lipocine buyer in Q2 2015 was Invesco, an estimated $7.85M added.
  • The largest Lipocine seller in Q2 2015 was Baker Bros. Advisors, an estimated $3.38M sold.

Based on aggregated 13F filings for Q2 2015.